In this large meta-analysis of 22 randomized trials of former smokers, the risk of cardiovascular events on treatment or within 30 days of discontinuation were not significantly different between the varenicline groups (0.63%) and the placebo groups (0.47%) (abstract). This opposes a former meta-analysis which found higher cardiac event rates within a year of discontinuing varenicline compared to placebo (abstract). Although these disparate results generate controversy about whether or not there is a risk, if there is it appears to be small.
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]